Arbutus Biopharma (ABUS) Current Assets (2010 - 2026)

Arbutus Biopharma has disclosed Current Assets across 17 years of filings, most recently posting $277.0 million for Q1 2026.

• Current Assets for Q1 2026 came in at $277.0 million, up 137.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $277.0 million (up 137.15% YoY), and the FY2025 annual result was $94.5 million, down 25.81% from the prior year.
• Current Assets came in at $277.0 million for Q1 2026 at Arbutus Biopharma, up from $94.5 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $277.0 million in Q1 2026 to a low of $94.5 million in Q4 2025.
• The 5-year median for Current Assets is $141.1 million (2022), against an average of $143.6 million.
• Across the five-year window, Current Assets sank 30.43% in 2025 and jumped 137.15% in 2026, its largest moves.
• Arbutus Biopharma's Current Assets stood at $151.1 million in 2022, then fell by 12.65% to $132.0 million in 2023, then fell by 3.57% to $127.3 million in 2024, then retreated by 25.81% to $94.5 million in 2025, then surged by 193.27% to $277.0 million in 2026.
• The last three Current Assets figures came in at $277.0 million (Q1 2026), $94.5 million (Q4 2025), and $97.4 million (Q3 2025), per Business Quant data.